NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Business Wire
– Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million –– Announces Chief Financial Officer transition – FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s Chief Financial Officer.Preliminary, Unaudited Fourth Quarter and Full-Year 2025 RevenueFor the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%.For the full-year 2025, NeoGenomics expects to report total revenue of approximately $727 million, representing year-over-year growth of 10%.“Our preliminary fourth quarter revenue reflects our ongoing commitment to being the cancer testing ‘partner of choice’ to pathologists and oncologists in the commu
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics (NASDAQ:NEO) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.MarketBeat
- NeoGenomics sees Q4 revenue of about $190M [Seeking Alpha]Seeking Alpha
- NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue [Yahoo! Finance]Yahoo! Finance
- NeoGenomics (NASDAQ:NEO) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- A Look At NeoGenomics (NEO) Valuation After Recent Share Price Momentum Shift [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 10/28/25 - Beat
NEO
Sec Filings
- 1/12/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 3
- NEO's page on the SEC website